Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Cancer Discov. 2021 May 12;11(11):2868–2883. doi: 10.1158/2159-8290.CD-20-1793

Figure 7.

Figure 7.

Mechanism by which MYB drives oncogene activation in inv(3)/t(3;3) AML. A CRISPR/Cas9 scan of the GATA2 translocated enhancer pinpointed a single regulatory element containing a MYB-binding motif critical for EVI1 expression (top). MYB preferentially occupies the translocated enhancer driving EVI1 expression. Inference with MYB downregulates EVI1 but not GATA2 levels (bottom).